1643979-48-9

Basic information

• Product Name: 3-AMINO-4-PHENYLPYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3-AMINO-4-PHENYLPYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-TRANS-3-AMINO-4-PHENYL PYRROLIDINE;TERT-BUTYL (3S,4R)-3-AMINO-4-PHENYLPYRROLIDINE-1-CARBOXYLATE
• CAS NO: 1643979-48-9
• Molecular Formula: C15H22N2O2
• Molecular Weight: 262.35
• Mol File: 1643979-48-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-AMINO-4-PHENYLPYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-4-PHENYLPYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(1643979-48-9)
• EPA Substance Registry System: 3-AMINO-4-PHENYLPYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(1643979-48-9)

Safety Data

• Hazardous Substances Data: 1643979-48-9(Hazardous Substances Data)

Upstream product

• 5153-67-3 nitrostyrene 
• 1096341-35-3 trans-1-benzyl-4-phenylpyrrolidin-3-amine 
• 1643979-48-9 (rac,trans)-tert-butyl-3-amino-4-phenylpyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.